Source: Annual Congress 2003 - Similarities and differences between β-2 agonists
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Cazzola, A. Salzillo, C. De Giglio, P. Noschese, G. D[ssqoute]Amato (Naples, Italy). Formoterol/budesonide (FBC) in the treatment of acute exacerbation of COPD. Eur Respir J 2003; 22: Suppl. 45, 1859

Member's Comments

No comment yet.

Related content which might interest you: Comparison of the acute effects of formoterol (F) and formoterol/budesonide combination (FBC) on blood-gas tensions in patients with acute exacerbation of COPD (AECOPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003 The estimation of respiratory muscles (RM) status by echodensitometry in male patients with acute exacerbation of COPD (AECOPD) Source: Annual Congress 2010 - Interaction between respiratory and peripheral muscles Year: 2010 Vascular-platelet hemostasis parameters in the stable phase and in acute exacerbation (AE) of COPD Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015 Co-morbidity and hospitalization rate in patients (pts) with acute exacerbation (AE) of COPD Source: International Congress 2015 – Different data in COPD Year: 2015 Cognitive decline following an acute exacerbation of COPD (AECOPD) Source: Virtual Congress 2020 – Investigations of COPD Year: 2020 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 Association of COPD inhaled  medication adherence with hospitalization for acute exacerbation of COPD (AECOPD) Source: International Congress 2017 – COPD management Year: 2017 Mucociliary clearance (MCC) disorders in patient with acute bronchitis (AB) and acute exacerbation (AE) of COPD and ways of it correction Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 NIV in COPD: acute exacerbation and beyond Source: ERS course 2015 Year: 2015 Prulifloxacin in the treatment of acute exacerbations of COPD (AECOPD) in cigarette smokers Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008 One year experience with acute COPD assessment service (ACAS) for patients with acute exacerbations of COPD Source: Eur Respir J 2006; 28: Suppl. 50, 178s Year: 2006 Acute effects of higher than customary doses of salmeterol (SM) and salbutamol (SB) in patients with acute exacerbation of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 Determinants of discharge treatment after hospitalization for an acute exacerbation of COPD Source: Annual Congress 2007 - Treatment and care of COPD Year: 2007 Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD Year: 2003 The effect of an acute exacerbation of COPD (AECOPD) on balance after pulmonary rehabilitation (PR): a prospective study Source: International Congress 2017 – Assessing the functional status of patients with COPD Year: 2017 COPD patients admitted in ICU for acute exacerbation: Impact of exacerbation factors on prognosis Source: International Congress 2016 – Dealing with the complexity of critically-ill patients Year: 2016 LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Formoterol (Modulite), tiotropium and their combination in patients with acute exacerbation of chronic bronchitis: preliminary data Source: Eur Respir J 2005; 26: Suppl. 49, 285s Year: 2005